Heart Failure

Higher Odds of Hypertension Seen in Older Women, Younger Men

October 3rd 2021, 5:00pm


New research presented at the AHA Hypertension Scientific Sessions 2021 showed that men aged 20 to 49 years and women 70 and older both had a greater risk of hypertension.

Dr Deepak L. Bhatt: There Is a Lot of Excitement for HFpEF Right Now

October 1st 2021, 2:00pm


In an interview for ESC Congress 2021, Deepak L. Bhatt, MD, MPH, executive director of interventional cardiovascular programs at Brigham and Women’s Hospital Heart & Vascular Center and professor of medicine at Harvard Medical School, describes the treatment outlook for patients with heart failure with preserved ejection fraction (HFpEF).

Reviewing Race and Kidney Disease in the NKF-ASN Task Force Report

September 28th 2021, 10:15pm


On this episode of Managed Care Cast, we speak with Susan Quaggin, MD, FASN, a nephrologist and the chief of nephrology/hypertension and director of the Feinberg Cardiovascular and Renal Research Institute at Northwestern University, as well as current president of the American Society of Nephrology (ASN). She discusses the recommendations of the National Kidney Foundation (NKF) and ASN Task Force on Reassessing the Inclusion of Race in Diagnosing Kidney Diseases and what comes next for laboratories, clinicians, and patients.

HIIT Improves Cardiorespiratory Fitness More Than Low-Intensity Exercise, Review Says

September 26th 2021, 12:00pm


For patients with heart failure and cardiovascular disease, high intensity interval training has a greater positive effect on cardiorespiratory fitness than moderate intensity continuous training.

Remove Race From Equation Used to Assess Kidney Function, Researchers Say

September 23rd 2021, 4:00pm


Long-awaited reports released Thursday call for eliminating race in estimated glomerular filtration rate equations and point to alternatives in an effort to eliminate disparities in chronic kidney disease.

Dr Stefan Anker: Patients With HFpEF Deserve a New Treatment

September 21st 2021, 7:00pm


With empagliflozin, we now have evidence that another treatment for patients with heart failure with preserved ejection fraction (HFpEF) is possible, said Stefan Anker, MD, PhD, FESC, professor of cardiology, Department of Cardiology, Charité Campus Virchow Clinic, Berlin, Germany, and principal investigator of the EMPEROR-Preserved study.

Diagnosis Patterns and Stress Testing Trends After Implementing High-Sensitivity Troponin Assay

September 17th 2021, 1:00pm


This study found that switching from a conventional troponin assay to a high-sensitivity troponin assay resulted in changes to diagnosis patterns and stress testing trends.

Mom’s Meals Launches Pilot Program for California Health Plan Members With Heart Failure

September 16th 2021, 6:49pm


The 6-month program provides nutrition education, healthy food and recipes, and home visits.

Lower Rehospitalization, Mortality Seen From Sacubitril/Valsartan Use for HFrEF

September 15th 2021, 12:00pm


Entresto (sacubitril/valsartan) was first approved for use in heart failure with reduced ejection fraction (HFrEF) in 2015.

Panel Outlines Updates on HF Treatment Developments, Recommendations for Guidelines

September 13th 2021, 4:30pm


In a panel at the 5th annual Heart in Diabetes Conference, John McMurray, MD, and Javed Butler, MD, highlighted recent pharmacological developments in heart failure (HF) and offered insights on overlooked areas in the field.